Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab versus placebo for preventive treatment of episodic migraine in pediatric patients
2019-002055-42Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Fremanezumab with Placebo (2 arms). Primary endpoint: Mean change from baseline in monthly average number of migraine days. Started Aug 2020; status: completed.
02
Drugs
fremanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2019-002055-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002055-42.